Hughes Caryn, Baker Matthew J
School of Chemical Engineering & Analytical Sciences, Faculty of Engineering & Physical Science, University of Manchester, Brunswick Street, Manchester, M13 9PL, UK.
WestCHEM, Department of Pure and Applied Chemistry, University of Strathclyde, Technology and Innovation Centre, 99 George Street, Glasgow, G1 1RD, UK.
Analyst. 2016 Jan 21;141(2):467-75. doi: 10.1039/c5an01858g.
This review will take a fresh approach from the patient perspective; offering insight into the applications of mid-infrared biomedical spectroscopy in a scenario whereby the patient presents with non-specific symptoms and via an extensive diagnostic process multiple lesions are discovered but no clear sign of the primary tumour; a condition known as cancer of unknown primary (CUP). With very limited options to diagnose the cancer origin, treatment options are likely to be ineffective and prognosis is consequentially very poor. CUP has not yet been targeted by infrared biospectroscopy, however, this timely, concise dissemination will focus on a series of research highlights and breakthroughs from the field for the management of a variety of cancer-related diseases - many examples of which have occurred within this year alone. The case for integration of mid-infrared (MIR) technology into clinical practice will be demonstrated largely via diagnostic, but also therapeutic and prognostic avenues by means of including cytological, bio-fluid and tissue analysis. The review is structured around CUP but is relevant for all cancer diagnoses. Infrared spectroscopy is fast developing a reputation as a valid and powerful tool for the detection and diagnosis of cancer using a variety of sample formats. The technology will produce data and tools that are designed to complement routine clinical practice; enhancing the ability of the clinician to make a reliable and non-subjective decision and enabling decreased levels of mortality and morbidity and gains in patient quality of life.
本综述将从患者角度采用全新方法；深入探讨中红外生物医学光谱学在患者出现非特异性症状且经过广泛诊断过程发现多个病变但无原发肿瘤明确迹象（即未知原发癌，CUP）的情况下的应用。由于诊断癌症起源的选择非常有限，治疗方案可能无效，因此预后非常差。CUP尚未成为红外生物光谱学的研究对象，然而，本次及时、简洁的传播将聚焦该领域一系列关于多种癌症相关疾病管理的研究亮点和突破——仅今年就有许多此类实例。将中红外（MIR）技术整合到临床实践中的理由将主要通过诊断途径来证明，同时也包括细胞学、生物流体和组织分析等治疗和预后途径。本综述围绕CUP构建，但对所有癌症诊断都具有相关性。红外光谱学正迅速成为一种使用多种样本形式检测和诊断癌症的有效且强大的工具。该技术将产生旨在补充常规临床实践的数据和工具；提高临床医生做出可靠且非主观决策的能力，并降低死亡率和发病率，提高患者生活质量。
